Increase of interferon-γ Inducible CXCL9 and CXCL11 serum levels in patients with active graves' disease and modulation by methimazole therapy

Thyroid

Volumn 23, Issue 11, 2013, Pages 1461-1469

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Corrado, Alda ^a   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; LIOTHYRONINE; THIAMAZOLE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HUMAN; IMMUNOMODULATION; MALE; NODULAR GOITER; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; THYROID FUNCTION; TOXIC GOITER;

ADULT; AGED; ANTITHYROID AGENTS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINE CXCL11; CHEMOKINE CXCL9; FEMALE; GOITER; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; MALE; METHIMAZOLE; MIDDLE AGED; PHENOTYPE; RECURRENCE; THYROID GLAND;

EID: 84887421007     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0485     Document Type: Article

References (49)

1. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P 2007 Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28:492-520. (Pubitemid 47236335)
2. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P 2003 Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278:289-295. (Pubitemid 36043575)
3. Luster AD, Ravetch JV 1987 Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 166:1084-1097. (Pubitemid 18024248)
4. Farber JM 1997 Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61:246-257. (Pubitemid 27149903)
5. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K 1998 Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187:2009-2021. (Pubitemid 28285570)
6. Colvin RA, Campanella GS, Sun J, Luster AD 2004 Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279:30219-30227. (Pubitemid 38937947)
7. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O, Kasuga A, Saruta T, Narumi S 2001 Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 24:510-515. (Pubitemid 32198422)
8. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of patients with recent onset Graves' disease. Am J Pathol 161:195-206. (Pubitemid 34760785)
9. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499. (Pubitemid 39518431)
10. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M 2005 Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152:171-177. (Pubitemid 40309561)
11. Garća-López MA, Sancho D, Sánchez-Madrid F, Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3 + lymphocytes. J Clin Endocrinol Metab 86:5008-5016. (Pubitemid 33020557)
12. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 59:207-213. (Pubitemid 36918657)
13. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M 2001 Cell cycle dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 107:53-63. (Pubitemid 32047414)
14. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M 2006 Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper-or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 154:651-658. (Pubitemid 43810850)
15. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M 2006 Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 64: 189-195.
16. Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, Miccoli M, Benvenga S, Paolicchi A, Ferrannini E, Fallahi P 2011 Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 55:288-293.
17. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, Ferrannini E, Fallahi P 2011 Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 96:1859-1863.
18. Antonelli A, Ferri C, Ferrari SM, Frascerra S, Ruffilli I, Caponi L, Ulisse S, Miccoli M, Miccoli P, Fallahi P 2012 High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C Motif) ligand 10. J Interferon Cytokine Res 32:74-80.
19. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, Orlando C, Ferrannini E, Fallahi P 2010 CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 95:E413-E420.
20. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E 2009 Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 94:1803-1809.
21. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Gelmini S, Minuto M, Pupilli C, Miccoli P, Sellari-Franceschini S, Ferrannini E, Fallahi P 2012 Peroxisome proliferator-activated receptor-a agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes. Mol Cell Endocrinol 349:255-261.
22. Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Okamoto H, Ferrannini E 2001 Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 126:426-431. (Pubitemid 34008713)
23. Qin Q, Liu P, Liu L, Wang R, Yan N, Yang J, Wang X, Pandey M, Zhang JA 2012 The increased but non-predominant expression of Th17-and Th1-specific cytokines in Hashimoto's thyroiditis but not in Graves' disease. Braz J Med Biol Res 45:1202-1208.
24. Nanba T, Watanabe M, Inoue N, Iwatani Y 2009 Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease. Thyroid 19:495-501.
25. McLachlan SM, Nagayama Y, Rapoport B 2005 Insight into Graves' hyperthyroidism from animal models. Endocr Rev 26:800-832. (Pubitemid 41428539)
26. Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M 2004 Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation 11:209-213. (Pubitemid 38916092)
27. Watson PF, Pickerill AP, Davies R, Weetman AP 1994 Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab 79:355-360. (Pubitemid 24256517)
28. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E 2006 Interferongamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 91:614-620. (Pubitemid 43236933)
29. Matsubayashi S, Kasuga Y, Sakatsume Y, Akasu F, Volpe R 1990 Serum interferon gamma levels in autoimmune thyroid disease. Clin Invest Med 13:271-274. (Pubitemid 20367955)
30. Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Crespillo- Gómez C, Berg J 2003 Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves' disease. Horm Metab Res 35:427-433. (Pubitemid 37378271)
31. Miyauchi S, Matsuura B, Onji M 2000 Increased levels of serum interleukin-18 in Graves' disease. Thyroid 10:815-819.
32. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM 1999 Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 84:435-439. (Pubitemid 29075665)
33. Mariotti S, Del Prete GF, Mastromauro C, De Carli M, Romagnani S, Ricci M, Pinchera A 1991 The autoimmune infiltrate of Basedow's disease: analysis of clonal level and comparison with Hashimoto's thyroiditis. Exp Clin Endocrinol 97:139-146.
34. De Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, Del Prete G 1993 Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 77:1120-1124. (Pubitemid 23345455)
35. Aniszewski JP, Valyasevi RW, Bahn RS 2000 Relationship betweendiseasedurationand predominant orbital Tcell subset in Graves' ophthalmopathy. J Clin EndocrinolMetab 85:776-780. (Pubitemid 32273668)
36. Domberg J, Liu C, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum WA, Schloot NC, Schott M 2008 Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res 40:416-421. (Pubitemid 351967134)
37. Cooper DS 1984 Antithyroid drugs. N Engl J Med 311:1353-1362. (Pubitemid 15129606)
38. Weetman AP, McGregor AM, Hall R 1984 Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clin Endocrinol (Oxf) 21:163-172. (Pubitemid 14096680)
39. Crescioli C, Cosmi L, Borgogni E, Santarlasci V, Gelmini S, Sottili M, Sarchielli E, Mazzinghi B, Francalanci M, Pezzatini A, Perigli G, Vannelli GB, Annunziato F, Serio M 2007 Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 195:145-155. (Pubitemid 350056008)
40. D́ez JJ, Hernanz A, Medina S, Bayón C, Iglesias P 2002 Serum concentrations of tumour necrosis factor-alpha (TNFalpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol (Oxf) 57:515-521. (Pubitemid 35216303)
41. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E 2000 Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 143:197-202. (Pubitemid 30622353)
42. Senturk T, Kozaci LD, Kok F, Kadikoylu G, Bolaman Z 2003 Proinflammatory cytokine levels in hyperthyroidism. Clin Invest Med 26:58-63. (Pubitemid 36741248)
43. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E 2007 Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 92:1485-1490. (Pubitemid 46556429)
44. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P 2006 Serum levels of the interferon-gammainducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93:1226-1231. (Pubitemid 44547021)
45. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM 1999 Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103:807-815. (Pubitemid 29152626)
46. Mahad DJ, Howell SJ, Woodroofe MN 2002 Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 72:498-502.
47. Comini-Frota ER, Teixeira AL, Angelo JP, Andrade MV, Brum DG, Kaimen-Maciel DR, Foss NT, Donadi EA 2011 Evaluation of serum levels of chemokines during interferon-£ treatment in multiple sclerosis patients: a 1-year, observational cohort study. CNS Drugs 25:971-981.
48. SzczuciDski A, Kalinowska A, Losy J 2007 CXCL11 (interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone. Eur Neurol 58: 228-232. (Pubitemid 350175891)
49. Davies TF, Roti E, Braverman LE, DeGroot LJ 1998 Thyroid controversy-stimulating antibodies. J Clin Endocrinol Metab 83:3777-3785.